MA-RHINOSTICS/LVL
14.11.2022 12:01:38 CET | Business Wire | Press release
Rhinostics Inc. is excited to announce an expanded partnership with LVL technologies GmbH, which includes Rhinostics’ reselling of LVL’s decapper instrument and LVL’s distribution of Rhinostics’ automated collection devices in Germany and Austria. By combining the Rhinostics’ sample collection device ingenuity with decapper technology, laboratories can benefit from an instantly scalable automated swab and small volume blood collection processing workflow. Automation breaks through manual bottlenecks during capping and recapping steps so that laboratories can increase throughput and consistency while also decreasing cumbersome steps as well as reagent and labor costs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221114005373/en/
Rhinostics and LVL technologies Partner to Provide Decapping Solutions for Automated Collection Device Workflows (Photo: Business Wire)
“Today, researchers, clinicians, and patients alike expect more when it comes to sample collection and diagnostic workflows from respiratory pathogens, sexually transmitted infections, genetic testing to cancer biomarkers and much more,” explained Cheri Walker, PhD, President and CEO of Rhinostics. “We’re excited to expand our partnership with LVL, our supplier of high-quality collection tubes to Rhinostics during the pandemic and beyond. The companies have enjoyed a close relationship, and we can now offer a full solution for our customers by launching a customized version of LVL’s robust decapper instrument to the market.”
“We are extremely pleased to expand our partnership with Rhinostics,” said Martin von Lueder, Chief Executive Officer of LVL. “We have watched Rhinostics bring industry changing, purpose-built sample collection devices that are automation-enabled to the market. The LVL decapper instrument is the perfect complement to their consumables, allowing improvements to inefficient swab and blood collection workflows. Additionally, we look forward to offering the Rhinostics products to our customers.”
As part of the partnership, the RHINObot™ has been optimized for use with the RHINOstic® Automated Swab – a patent-pending sample collection device that integrates a unique polypropylene-based swab with an automatable cap.
Nasal, buccal, or vaginal samples may be comfortably collected in a clinical setting or easily self-collected as part of an at-home test kit. After collection, the swab is securely screwed into a small, barcoded transport tube. This transport tube may be shipped without use of viral transport or other media to reduce reagent costs as well as risks of leaking, accidental biohazard exposure, and potential PCR interference due to VTM or other media components. Dry shipment also enables greater sample concentrations to boost confidence in sensitive PCR, next generation sequencing (NGS), ELISA methods, even at very low pathogen levels.
Once in the laboratory, samples may be loaded onto the RHINObot™ for automated decapping and capping of up to 96 samples in less than 1 minute. This hands-free workflow eliminates user variability and reduces labor time by up to 80+% to significantly decrease per-test costs.
The collaborative agreement will include co-promoting the RHINOstic® and RHINObot™ solution along with marketing and educational initiatives aimed at making customers aware of the increased convenience, speed, and consistency of the automated workflow.
About Rhinostics
Rhinostics is at the forefront of revolutionizing sample collection. As a spin-out company from Harvard University and Wyss Institute, we are taking a radical new approach to sample collection device design and function. COVID-19 cast light on the urgent need to improve laboratory workflows. Rhinostics was born to meet the moment. Our united mission is to revolutionize laboratory workflows, one purpose-built collection device at a time. We improve sample collection comfort and performance while bringing efficiencies to the laboratory to remove costs and save time compared to traditional sample collection intake. Our groundbreaking technologies include functional design, novel materials, and automation solutions for removing caps and rapid accessioning for hands-free workflows. This enables robust high-throughput assays from start to finish with minimal human intervention, saving time and reducing costs.
Rhinostics’ initial product, the RHINOstic® Automated Swab, aids testing broad diagnostic and life science workflows, in areas like respiratory disease, genomics, STDs, forensics and much more. The company continues to innovate, launching a novel small-volume blood collection device, the VERIstic™, and developing a pipeline of novel sample collection devices that are purpose-built for their application combined with automation enablement. To learn more, visit https://www.rhinostics.com.
About LVL
LVL technologies is a leading global manufacturer of 2D coded tubes in the automation-friendly SBS format, including the necessary technical infrastructure. Based in Crailsheim, Germany, the company supplies organizations and companies in more than 50 countries with high-quality storage tubes for demanding long-term sample storage. Applications range from clinical and veterinary diagnostics and biobanking to compound management and research applications in biotechnology. The latest technical development is the fully automatic TLM 864 Tube Laser Marker.
To learn more, visit https://www.lvl-technologies.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005373/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 13:00:00 CEST | Press release
Transaction accelerates Mobix Labs’ global aerial intelligence strategy and National Security Matters Initiative Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performanc
Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 13:00:00 CEST | Press release
Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years If approved, Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab would become first new treatment in the EU in more than a decade for first-line HER2 positive metastatic breast cancer Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP)
SLB Announces Second-Quarter 2026 Results24.7.2026 12:50:00 CEST | Press release
Revenue of $8.97 billion increased 3% sequentially and 5% year on year GAAP EPS of $0.52 increased 4% sequentially and decreased 30% year on year EPS, excluding charges and credits, of $0.55 increased 6% sequentially and decreased 26% year on year Net income attributable to SLB of $786 million increased 5% sequentially and decreased 22% year on year Adjusted EBITDA of $1.90 billion increased 7% sequentially and decreased 7% year on year Cash flow from operations was $1.36 billion and free cash flow was $716 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the second-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722694386/en/ The exterior of the SLB headquarters in Houston, Texas.Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2026Mar. 31, 2026Jun. 30, 2025SequentialYear-on-yearRevenue $8,972 $8
NIQ Expands GenAI Capabilities Across gfknewron, Turning Trusted Intelligence into Decisions Faster24.7.2026 12:30:00 CEST | Press release
New capabilities help businesses uncover trends faster, simplify complex analysis, and accelerate confident decision-making NIQ (NYSE: NIQ), a leader in consumer intelligence, today announced the expansion of AI-powered Smart Insights across its gfknewron® platform. By bringing together markets and categories into a single view, gfknewron enables businesses to transform complex market, consumer and supply chain data into clear, actionable intelligence quickly. The latest enhancements help users identify trends, opportunities and performance drivers more quickly, reducing the time required to analyze large datasets and accelerating confident decision-making across teams. As brands and retailers face growing pressure to respond quickly to changing consumer behavior and market dynamics, the ability to unlock meaningful insights from increasingly rich datasets has become a significant competitive advantage. As AI is only as effective as the intelligence behind it, Smart Insights helps busi
Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 10:05:00 CEST | Press release
The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200 MM/A) radars to protect the Romanian airspace. This government-to-government agreement underlines the high level of partnership between France and Romania, within the framework of the European Union’s SAFE funding programme, in order to bolster Europe’s defence capabilities. The GM200 MM/A is part of Thales’ proven Ground Master radar family, which has already been deployed in over 40 countries, including now in Romania. In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-governm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom